Oncology drug health technology assessment recommendations: Canadian versus UK experiences

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2014

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 6,212 followers.

Why bother with CEA then? Oncology recs in Canada not influenced by #healtheconomics - http://t.co/dYZzjx0XlD

Why bother with CEA then? Oncology recs in Canada not influenced by #healtheconomics - http://t.co/dYZzjx0XlD

Why bother with CEA then? Oncology recs in Canada not influenced by #healtheconomics - http://t.co/dYZzjx0XlD

Oncology drug #HTA recommendations CDN vs UK experiences http://t.co/BFLwasPFUH via @ChabotIsabelle1 #HTAC

Oncology drug health technology assessment recommendations: Canadian versus UK e... http://t.co/oSuWxYZQwr

Oncology drug health technology assessment recommendations: Canadian versus UK experiences http://t.co/Ubp0tq2bvh